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Abstract
Prospective registration of study protocols in clinical trial registries is a useful way to
minimize the risk of publication bias in meta-analysis, and several clinical trial registries
are available nowadays. However, they are mainly used as a tool for searching studies and
information submitted to the registries has not been utilized as efficiently as it could. In
addressing publication bias in meta-analyses, sensitivity analysis with the Copas selection
model is a more objective alternative to widely-used graphical methods such as the funnel-
plot and the trim-and-fill method. Despite its ability to quantify the potential impact of
publication bias, a drawback of the model is that some parameters not to be specified.
This may result in some difficulty in interpreting the results of the sensitivity analysis.
In this paper, we propose an alternative inference procedure for the Copas selection
model by utilizing information from clinical trial registries. Our method provides a simple
and accurate way to estimate all unknown parameters in the Copas selection model. A
simulation study revealed that our proposed method resulted in smaller biases and more
accurate confidence intervals than existing methods. Furthermore, two published meta-
analyses had been re-analysed to demonstrate how to implement the proposed method in
practice.
Keywords: Clinical trial registry; Meta-analysis; Publication bias; Research synthesis;
Selection model
1 Introduction
Publication bias is one of the most important concerns in systematic reviews and meta-analyses.
Part of the issue is that authors and scientific journals are likely to publish studies with
statistically significant results than inconclusive studies[1]. To be statistically significant, the
studies with small sample size need to show larger treatment effects, which is known as the
small-study effect[2]. Thus, this may force us to analyze selective samples from the population
of interest, and the standard meta-analysis techniques may suffer from this selection bias, which
is referred to as publication bias.
The funnel plot is a simple and widely-used graphical tool to check for publication bias,
which is defined by plotting the estimate of the effect size such as the log-odds ratio or the
log-hazard ratio as the horizontal axis and the related measure of precision such as the square
root of the sample size or the inverse of the standard error as the vertical axis. One can
address the publication bias by examining asymmetry of the funnel plot visually and more
formal statistical evaluation of the funnel-plot asymmetry can be made with a regression based
test[3, 4] or a rank-based test [5, 6]. The trim-and-fill method is a nonparametric method to
adjust publication bias utilizing the funnel-plot asymmetry[7].
All these methods are simple to apply and are widely used in practice. However, publication
bias is not the only reason for asymmetry of the funnel plot; Egger et al.[3] listed different
potential reasons for the funnel-plot asymmetry including the between-study heterogeneity and
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others. Then, detection of the publication bias by the funnel plot may be subjective and the
trim-and-fill method may not work well[8, 9]. Alternatively, several sensitivity analysis methods
have been developed. Copas and colleagues introduced the Heckman-type parametric selection
model, which was originally proposed in the econometrics literature[10], to describe a selective
publication process in meta-analysis. In this paper, this selection model is referred as the Copas
selection model[11, 12]. The sensitivity analysis with the Copas selection model has several
advantages over existing alternative sensitivity analysis methods[13, 14, 15]; a user-friendly R
package metasens is available for the Copas-Shi selection model[11, 12], and its performance
was empirically examined[16, 17]. Thus, we focus on this selection model in this paper.
The Copas selection model consists of a pair of models; one is for the outcome, such as
the log-odds ratio or the log-hazard ratio reported in publications, and the other is a model
for the latent variable describing a selective publication process. It’s hard to estimate all the
parameters in the Copas selection model, and thus a series of papers by Copas and colleagues
took a sensitivity analysis approach; some parameters were fixed as sensitivity parameters in a
certain range, and the impact on the estimate of interest was studied. However, it’s not easy
to define an appropriate range for the sensitivity parameters.
Prospective registration of study protocols in clinical trial registries is a useful non-
statistical approach for publication bias. The International Committee of Medical Journal
Editors (ICMJE) initiated a trials-registration policy as a condition for publication in its
member journals in July 2005[18], which promoted the development and utilization of the
clinical trial registries. ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home) is one of
the early examples which was established in 2000 and is nowadays a very popular registry
with 334,954 registered studies in April 2019. World Health Organization’s (WHO) Inter-
national Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/trialsearch/)
is another well-known clinical trials registry which was constructed after the initiation
of ICMJE’s policy and has been supported by the WHO. FDA (US Food and Drug
Administration) database (https://www.accessdata.fda.gov/scripts/cder/daf/) contains
information about products approved by the FDA for human use in the United States. Besides,
EU clinical trials register (https://www.clinicaltrialsregister.eu/ctr-search/search)
and ISRCTN (https://www.isrctn.com/) are also well-developed and widely used in recent
years as well as many national registries that often also provide lay summaries in the local
language[19, 20].
Baudard et al. [21] investigated 14 meta-analyses and showed that by incorporating the
information from clinical trial registries, the effect size estimates might change by 29%. It
indicated that searching clinical trial registries may be useful to reduce the bias due to selective
publication. On the other hand, although clinical trial registries provide potentially useful
information of the registered clinical trials (e.g., study design, target sample size, development
phase), they are used only as a tool to search for studies[22]. Information on unpublished studies
provided by clinical trial registries is not formally incorporated in the analyses. To the best of
knowledge, only two papers mentioned the use of clinical trial registries in statistical inference.
Matsuoka et al. [23] proposed a publication bias detection method by utilizing the planned
sample size from World Health Organization’s (WHO) International Clinical Trials Registry
Platform (ICTRP). Mavridis et al. [24]utilized FDA database to construct a prior distribution
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of parameters in their Bayesian Copas-type model for sensitivity analysis in network meta-
analysis.
In this paper, we improve statistical inference for the Copas-Shi selection model utilizing
the information from clinical trial registries. To be specific, utilizing the planned sample size of
unpublished studies, which are provided by most clinical trial registries, we propose a method
that fit by the maximum likelihood method. All the unknown parameters can be estimated
from data, and statistical inference can be conducted according to the standard maximum
likelihood theory. In addition to the confidence interval with the normal quantile according
to the maximum likelihood theory, we also propose two modified confidence intervals aiming
improvement of performance with the small number of studies. Through numerical studies,
we observed that our method outperformed existing methods with smaller biases and coverage
probabilities closer to the nominal level. Thus, by utilizing the information of unpublished
studies from clinical trial registries, inference based on the Copas selection model can be
improved.
The remainder of this paper is organized as follows. In Section 2, we introduce two
motivating meta-analyses. In Section 3, we briefly review the sensitivity analysis method of
Copas and Shi[11, 12], and then introduce our new inference procedure by utilizing clinical trial
registries. In Section 4, we conduct a series of simulation studies motivated by the tiotropium
study to evaluate the performance of our proposed method in comparison to other competitive
approaches. In Section 5, we revisit the two studies in Section 2 to illustrate the proposed
method. Finally, we discuss some limitations and further research in Section 6.
2 Motivating examples
2.1 Tiotropium study
Karner et al.[25]conducted a Cochrane review of tiotropium versus placebo in COPD. The
primary outcome was COPD exacerbations, which was defined as a complex of respiratory
events or symptoms (new onset or an increase in at least one of cough, sputum, dyspnoea or
wheeze) that lasted at least three days and required treatment with antibiotics and/or systemic
corticosteroids. In each study, the odds ratio for the event of one or more exacerbations was
used to compare the treatment and placebo groups. In the meta-analysis by Karner et al.[25],
22 studies were analyzed using a random-effects model, and the pooled odds ratio was reported
as 0.78 with a 95% confidence interval of [0.70, 0.87].
To assess the potential risk of publication bias, Karner et al.[25]conducted the Egger’s test
with the p-value of 0.22 and concluded no serious concern of publication bias. However, our
additional application of the Macaskill’s regression test[4] gave a p-value of 0.06, suggesting the
funnel-plot asymmetry. Then, publication bias might be a concern. Karner et al. [25]made
their efforts to search the studies with results submitted on ClinicalTrials.gov. We conducted
a more comprehensive search of multiple registries, including ClinicalTrials.gov, World Health
Organization’s (WHO) International Clinical Trial Registry, EU clinical trials register, FDA
database, and ISRCTN platform. We used the following terms: Tiotropium or Spiriva or
HandiHaler or Respimat for the search. They were the same as used in the meta-analysis of
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Karner et al. [25], and we also set primary completion date before February 28, 2012, which
aimed to be consistent with the original meta-analysis. We detected 10 related studies on these
registries, among which 8 came from ClinicalTrials.gov, 1 came from EU clinical trials register,
and 1 came from World Health Organization’s (WHO) International Clinical Trials Registry.
Two of them reported the outcome measure and were incorporated with published studies, and
8 studies without results were deemed as unpublished studies. Finally, we got the tiotropium
dataset with 24 published studies and 8 unpublished studies with information of sample size
only (see Table S1 in Web-appendix A).
2.2 Clopidogrel study
The second example is about the comparison of high and standard maintenance-dose clopidogrel
on major adverse cardiovascular/cerebrovascular events (MACE/ MACCE) by Chen et al.[26].
The original meta-analysis included 12 studies and reported pooled odds ratio as 0.6 based
on the fixed-effect model with a 95% CI of [0.43, 0.83], and no significant bias was concluded
with the Egger’s test (p=0.25). However, we rerun the Macaskill’s test, which suggested funnel-
plot asymmetry with a P value of 0.02. We took the procedure as given in the first example
and identified 3 unpublished studies from ClinicalTrials.gov by following terms: Clopidogrel or
Plavix or Iscover, with completion date before August 31, 2013. The resulting dataset was
presented in Table S2 in Web-appendix A.
3 Inference procedures for the Copas selection model
3.1 Brief review of the sensitivity analysis method by Copas and Shi
In order to evaluate the potential impact of publication bias on estimation of the treatment
effect, Copas and Shi [11] introduced a sensitivity analysis method. Suppose we conduct a
meta-analysis of N studies. Let θˆi be the estimated treatment effect of the ith study such as
the log-odds ratio or the log-hazard ratio, and si be an estimate of its standard error. We
assume that (θˆi, si) is available for i = 1, 2, ..., N . To integrate the treatment effects over the
studies, we consider the standard random-effects model with
θˆi = θi + σiǫi, θi ∼ N(θ, τ2), ǫi ∼ N(0, 1), (1)
where θi is the study-specific treatment effect of the ith study, which is a random-effect following
a normal distribution with mean θ and between-study variance τ2, and σ2i is the true within-
study variance of the outcome θˆi. The random elements θi and ǫi are assumed to be independent.
To describe the selective publication process, Copas and Shi [11, 12] considered the following
model
Yi = α0 + α1/si + δi, δi ∼ N(0, 1), corr(ǫi, δi) = ρ, (2)
where corr(ǫi, δi) denotes the correlation coefficient between ǫi and δi. The ith study is assumed
to be published if and only if Yi > 0. The term α0 +α1/si models the small study effect. That
is, studies of high precision are more likely to be pulished. The correlation coefficient ρ is
responsible for describing the influence of the outcome θˆi on likelihood of publication. Copas
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and Shi[11] considered to make inference by maximizing the likelihood function conditional on
the study being published. The conditional likelihood function is given by
Lobs(θ, τ, ρ, α0, α1; si) =
N∑
i=1
[
logf(θˆi|Yi > 0, si)
]
=
N∑
i=1
[
−1
2
log(τ2 + σ2i )−
(θˆi − θ)2
2(τ2 + σ2i )
− logΦ(α0 + α1/si) + logΦ(vi)
]
, (3)
where f(·|Yi > 0, si) is the probability density function of θˆi conditional on Yi > 0 and si.
Φ(·) is the cumulative distribution function of the standard normal distribution, and vi ={
α0 + α1/si + ρσi(θˆi − θ)/(τ2 + σ2i )
}
/
√
1− ρ2σ2i /(τ2 + σ2i ). In meta-analysis literatures, si is
usually regarded as being equal to σi and known. This is relevant approximately at least when
the number of subjects is sufficiently large. Copas and Shi[11, 12]took care of underestimation
of σi due to publication bias, and then they utilized the quantity var(θi|si, Yi > 0) to estimate
σ2i in inference of their selection model. As argued by Copas and Shi[11, 12], the log-likelihood
function (3) may take its maximum over a very flat plateau, and then it may be computationally
very challenging to estimate all the parameters simultaneously. Thus Copas and Shi[11, 12]
proposed that the vector (α0, α1) was fixed as sensitivity parameters, and (θ, τ, ρ) was estimated
by maximizing the conditional log-likelihood function (3). One can examine how the estimate
θˆ for the overall treatment effect θ would be influenced by the assumed selective publication
process. Since we do not know the true value of (α0, α1), we should apply this method with
various choices for the parameter vector (α0, α1) in a certain range. According to the formula
by Copas and Shi[11], one can translate (α0, α1) into the expected numbers of unpublished
studies by M =
∑N
i=1 {1− P (Yi > 0|si)} /P (Yi > 0|si), which is more interpretable. Then,
one can evaluate how biased the estimate of the treatment effect θ is with a certain number
of unpublished studies behind. Although such a consideration provides nice insights about
robustness of meta-analysis results, it is still unclear what range of the number of unpublished
studies is sufficient to be considered.
3.2 Proposed inference procedure utilizing clinical trial registries
In addition to the N published studies, we suppose that there are M unpublished studies
identified by searching clinical trial registries. Without loss of generality, the first N studies
are published and the last M studies are unpublished. Items required at registration are not
necessarily common among clinical trial registries. For example, FDA database provides the
sample size of each experimental group in its summary review PDF document, but other clinical
trial registries may not give it. However, all the clinical trial registries we referred provide the
planned total sample size (not separately by the experimental groups) of each study. Thus,
we suppose the triple (ni, θˆi, si) is available for i=1,2,...,N (published studies), and only ni is
available for i=N+1,..,N+M (unpublished studies). A binary variable Di = I(Yi > 0) denotes
the publication status (published/unpublished) of each study. Instead of the model (2), we
employ an alternative selection model
Yi = α0 + α1
√
ni + δi, δi ∼ N(0, 1), (4)
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which was used by Copas[27]. For the models (1) and (4), we introduce the maximum likelihood
approach as follows.
Considering the likelihood function of the published and the unpublished studies, the log
likelihood is given by
Lfull(θ, τ, ρ, α0, α1) =
N∑
i=1
[
logf(θˆi|Yi > 0;ni) + logP (Yi > 0;ni)
]
+
N+M∑
i=N+1
[logP (Yi < 0;ni)]
=
N∑
i=1
[
−1
2
log(τ2 + σ2i )−
(θˆi − θ)2
2(τ2 + σ2i )
+ logΦ(v˜i)
]
+
N+M∑
i=N+1
{log[1− Φ(α0 + α1√ni)]} , (5)
where v˜i =
{
α0 + α1
√
ni + ρσi(θˆi − θ)/(τ2 + σ2i )
}
/
√
1− ρ2σ2i /(τ2 + σ2i ). Following the
treatment often made in meta-analysis literature, we suppose that σi = si. By maximizing this
log-likelihood function (5), we can estimate all the parameters (θ, τ, ρ, α0, α1) simultaneously,
and the resulting maximum likelihood estimator is denoted by (θˆ, τˆ , ρˆ, αˆ0, αˆ1). Maximization
of the log-likelihood function can be implemented with the standard non-linear optimization
techniques. Here, we employ the constraint optimizer L-BFGS-B method in the nlminb()
function in R (package stats, version 3.6.2) to do this. Statistical inference can be conducted
following the standard maximum likelihood theory.
4 Simulation study
4.1 Methods to be compared
Simulation studies were carried out to evaluate the performance of our new inference procedure.
We investigated whether or not the proposed method outperforms the Copas sensitivity analysis
method. For reference, we also compared it with standard random-effects meta-analysis using
the restricted maximum likelihood (REML) estimation, which did not account for selective
publication process. In addition to the standard REML confidence interval based on normal
quantiles, the Hartung and Knapp method[28, 29] was applied using t -quantiles and rescaled
standard errors, which is referred to as REML.KnHa in the following. As outlined in Section
3, the Copas method is a sensitivity analysis approach resulting in multiple estimates under
several settings of the number of unpublished studies. For comparison with other methods, we
took the estimate of the treatment effect with the smallest number of unpublished studies of
the p-value of the goodness-of-fit test larger than 0.1[11], which is presented in the output of
Copas function in metasens package[30]. For the REML, we used the commonly used metafor
package with method option equal to “REML” and test equal to “knha” to obtain the CI with
the Hartung and Knapp method.
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4.2 Data generation
We mimicked meta-analyses motivated by the tiotropium study. Suppose each study aimed to
compare two groups of the treatment group and the control group with respect to a binary
outcome. The log-odds ratio was used as the summary measure of the treatment effect between
two groups. Let θˆi in the model (1) denoted the empirical log-odds ratio of the ith study. We
set θ = −0.25 and τ=0.05, 0.15 or 0.3. The total number of studies including published and
unpublished was set as 15, 25, 50 or 100. We generated datasets according to the models (1) and
(4) as follows. At first, we generated θi ∼ N(θ, τ2), which was the true log-odds ratio of the ith
study. Next, we generated individual participant data of the two groups with the log-odds ratio
of θi. We set the true event rate of the control group from the uniform distribution U(0.2,0.9),
and then set the event rate of treatment group satisfying the log-odds ratio of θi. Similarly
to Kuss[31], the total sample size of each study was generated from LN(5,1), the log-normal
distribution with the location parameter 5 and scale parameter 1, and the minimum sample size
was restricted to 20 patients (values below 20 were rounded up to 20). Subjects were allocated
to the two groups with probability of 0.5. With the generated individual participant data, we
calculated an empirical log odds ratio θˆi and its standard error si. Yi in the model (4) was
generated according to the conditional distribution,
Yi|θˆi ∼ N(α0 + α1
√
ni + ρσi(θˆi − θ)/(τ2 + σ2i ), 1− ρ2σ2i /(τ2 + σ2i )) (6)
and set Di = I(Yi > 0), which entailed us to generate (θˆi, Yi) from the joint distribution defined
by the models (1) and (4). The parameters (α0, α1) were set based on our consideration for the
publication rate of a study with the minimum sample size of 20 and that with a large sample
size of 500, which were denoted by P20 and P500, respectively. Set P500 = 0.99, reflecting our
belief that a study with 500 patients had sufficiently large probability to be published, and P20
was set to 0.1, 0.3 or 0.5, which represented our different concern to the publication rate of
a small study with sample size of 20. Thus according to the model (4), we could derive the
parameters (α0, α1) by solving the equations P20 = Φ(α0+α1
√
20) and P500 = Φ(α0+α1
√
500).
Then we got three pairs of (α0, α1) as (-2.18,0.20), (-1.24,0.16) and (-0.58,0.13), which resulted
in 40%, 27% and 19% unpublished studies on average in the simulated meta-analyses. The
parameter of ρ was set to -0.4 or -0.8, and for each ρ we investigated 3 scenarios of τ (0.05, 0.15
or 0.3). For each scenario, we generated 1000 simulated meta-analyses.
In Figure 1, we presented funnel plots of randomly selected simulated meta-analyses under
different settings of (ρ, τ) when the total number of published and unpublished studies was 50.
The filled and open circles represent published and unpublished studies, respectively, and we
observed our simulation setting successfully simulated the selective publication process often
observed in practice. The bold vertical line represents the true θ and the dashed vertical line is
the REML estimate with published studies. They were certainly different and thus publication
bias had certain impacts in simulated data.
4.3 Simulation results
The properties of each method were assessed by evaluating biases and standard errors of the
estimates for θ and average lengths and coverage probabilities of two-tailed 95% confidence
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intervals of θ. Following the standard maximum likelihood theory, we constructed the two-
tailed 95% confidence interval for the estimates of θ with our new proposal by θˆ±Z1−α
2
×
S.E.(θˆ), where Z1−α
2
denoting the 1 − α2 quantile of the standard normal distribution, and
S.E.(θˆ) is calculated by the inverse of the Fisher information matrix. The results for this
confidence interval were denoted by MLE(N) in the summary table. All these methods were
implemented with non-linear optimization techniques, thus we also summarized the number of
converged cases (NOC ) in each scenario. For our method, the non-convergence was defined
as a failure in optimization with negative hessian matrix or unsuccessful convergence based on
the convergence indicator in the output of nlminb function. For the Copas sensitivity analysis
method, we followed the rule of Copas function[16, 30].
Results of the simulation studies with (α0, α1)=(-2.18,0.2) were reported in Table 1 (ρ =
−0.4) and Table 2 (ρ = −0.8), respectively. The datasets for Tables 1 and 2 had around
40% unpublished studies on average. In almost all the simulated datasets, the log-likelihood
was successfully maximized and then gave estimates. In all the scenarios, the REML had
considerable biases. With ρ = −0.8 (Table 2), biases were larger, reflecting that ρ = −0.8
modeled a more selective publication process. Both the Copas method and our new proposal
decreased biases and ours had the smallest biases in most scenarios. With larger number of
studies (N=50 and 100), the maximum likelihood estimator tended to have very negligible biases,
and the confidence intervals based on the maximum likelihood theory (MLE(N)) had empirical
coverage probabilities close to the nominal level of 95%. With smaller number of the studies
(N=15 and 25), our method successfully decreased biases. However, coverage probabilities might
not be close to the nominal level and were not satisfactory when between-study heterogeneity
was moderate or substantial (τ = 0.15 and 0.3). We demonstrated results of the simulation
studies with (α0, α1)=(-1.24,0.16) in Tables S3 and S4, and that with (α0, α1)=(-0.58,0.13) in
Tables S5 and S6 in Web-appendix B. Findings were very similar to discussed above based on
Tables 1 and 2.
4.4 Modified confidence intervals
To improve the coverage probabilities with smaller number of studies, we introduced two
modifed confidence intervals. As suggested by Follmann and Proschan[32], an alternative
confidence interval θˆ±t(N−1);(1−α
2
)× S.E.(θˆ) may be used, where t(N−1);(1−α
2
) denoting
the 1 − α2 quantile of Student-t distribution with N − 1 degree of freedom. Further
modification was also considered by mimicking the idea of the improved estimator of
variance which was proposed by Knapp and Hartung[33]in the meta-regression context; we
modified the standard error of θˆ by S.E.(θˆ)♯=Max(S.E.(θˆ)MLE , S.E.(θˆ)REML−KnHa) , where
S.E.(θˆ)REML−KnHa was the estimator of standard error with HK-adjusted REML method,
reflecting our belief that the standard error of our proposal should be no less than the estimator
of methods without considering the selcetive publication process for the additional uncentainty
of unpublished studies. That is, a more conservative confidence interval was calculated by
θˆ±t(N−1);(1−α
2
)×S.E.(θˆ)♯. We applied these two confidence intervals to the simulated meta-
analyses, results were also shown in Tables 1 and 2 and Tables S3-S6 in Web-appendix B,
referring as MLE(T) and MLE(SE♯), respectively. We observed that these two confidence
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intervals MLE(T) and MLE(SE♯) gave certain improvement. In particular, MLE(SE♯) had
much improved emprical coverage probabilities with N=15.
5 Re-analysis of two motivating examples with clinical trial
registries
In this section, we applied our new inference procedure to the two case studies of the tiotropium
study and clopidogrel study introduced in Section 2. To present data of unpublished studies as
well as that of published studies, we propose to use a modified funnel-plot adding information
of the planned sample size of unpublished studies with horizontal lines passing the y-axis at
√
ni. The modified funnel-plots for tiotropium study and clopidogrel study were presented in
Figures 2 and 3, respectively. We could observe that for both of the two motivation cases, all
the unpublished studies concentrated on the lower part of the funnel-plot. To the data, we
applied our proposed method, as well as other related methods used in the simulation section,
and the results for the two motivation cases were summarized in Tables 3 and 4, respectively.
As presented in Subsection 2.1, for the tiotropium study, we identified 24 published and 8
unpublished studies. By applying the linear mixed-effect model for the log-odds ratios with
the REML method, the integrated odds ratio was obtanied as 0.768 with a two-tailed 95% CI
of [0.697,0.847] based on the normal approximation. The Knapp and Hartung modification
gave a similar CI of [0.691, 0.854]. According to the sensitivity analysis by the Copas model,
one can observe that as increasing the number of unpublished studies, the odds ratio increased
up to 0.811, which was corresponding to the case of 13 unpublished studeis. The overall
treatment effect was significantly different from unity even with 13 unpublished studies. Suppose
we have 8 published studies behind which was same with our findings from the clinical trial
registries, Copas sensitivity analysis method gave the pooled odds rato as 0.803 with a 95% CI
of [0.717, 0.898]. Our proposed method gave the integrated estimate of 0.787 with two-tailed
95% confidence intervals [0.710, 0.873] and [0.706, 0.878] based on the standard normal quantile
and t-quantile, respectively. In this case, the standard error from our method was larger than
the standard error from REML with the Knapp and Hartung modification, so the modified
confidence interval MLE(SE♯) was same with MLE(T). To summary, all the methods provided
statistically significant effect of tiotropium, indicating that selective publication might have not
been much of an issue here.
For the clopidogrel study which we introduced in Subsection 2.2, with only 3 unpublished
studies identified from the clinical trial registries, the estimates with and without consideration
of publication bias were considerably different. By applying the REML with 12 published
studies, the estimator of the pooled odds ratio was 0.579 and with two-tailed 95% CIs of
[0.375, 0.892] and [0.385, 0.871] based on the normal quantile and the Knapp and Hartung
modification, respectively. Both of them supported the conclusion that the high maintenance-
dose clopidogrel significantly reduced the incidence of MACE/MACCE in comparison to the
standard-maintenance-dose clopidogrel. However, the sensitivity analysis by the Copas model
showed that as the number of unpublished studies increased up to 4, the statistical significance
of the High-maintenance-dose clopidogrel disappeared, and as high as 39% change in estimates
of odds ratio could be observed with 6 unpublished studies. Our proposed method gave the
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integrated estimate of 0.692, and a two-tailed 95% CI based on the normal approximation was
given as [0.496, 0.967], whose upper bound was very close to 1. The modified CIs introduced in
Subsection 4.4 could be obtained as [0.476, 1.007] (MLE(T)) and [0.460, 1.041] (MLE(SE♯)),
respectively. These results suggested that the significant effect of the high maintenance-dose
clopidogrel might be marginal and should be interpreted with caution.
6 Discussion
By utilizing the information on unpublished studies obtained from the clinical trial registries,
we proposed a new inference procedure for the Copas selection model, which provides more
objective evaluation of publication bias than the widely-used funnel plot and trim-and-fill
method[16, 17]. All the unknown parameters in the Copas selection model can be estimated
from data with the proposed method. It resolved the issue of the sensitivity analysis approach
that some unknown parameters had to be fixed in a certain range, and then gave a more
insightful interpretation. Recently, Ning et al. [34]proposed a method to estimate all the
unknown parameters. Whereas their method strongly relied on an imputation based on funnel-
plot symmetry, our method does not.
Here, we would like to address some issues in clinical trial registries. Firstly, different
clinical trial registries may give inconsistent information. A comparison of results between
ClinicalTrials.gov and FDA database by Schwartz et al.[35]showed the planned sample size
registered on the clinical trial registries were not always consistent with the final sample size for
statistical analysis. Besides, as acknowledged by Fleminger et al.[36] the status of the studies
might be inconsistent between EUCTR and ClinicalTrials.gov, the studies registered on EUCTR
which marked with “completed” may marked with “onging” in ClinicalTrials.gov. Secondly, no
clinical trial registry could cover all the related studies[37, 38, 39]. Thirdly, it is hard to
integrate multiple clinical trial registries automatically since unique identifier of a study is not
available among registries (e.g. World Health Organization’s (WHO) International Clinical
Trial Registry Platform (ICTRP)). Due to these issues of clinical trial registries, comprehensive
search of multiple clinical trial registries was recommended in practice.
Clinical trial registries provide various information other than sample size. ClinicalTri-
als.gov’s search result contains 26 items in the list and analysis result if the investigator
submitted, ICTRP contains 40 items in the result file, and FDA database provide much more
details about the registered clinical trials. As acknowledged by several cross-sectional studies,
information such as funding type (government, industry or academic) and region may possibly
play important roles in the publication status[40]. In addition, information of ongoing studies
are also available, although we did not use them in this paper. How to take a further utilization
of the clinical trial registry would deserve more attention.
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Figure 1: Funnel plots of randomly selected published (filled circles)/unpublished (open circles)
studies in simulated datasets with N +M = 50 under different settings of τ and ρ
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Figure 2: A funnel-plot for the tiotropium study being modified by adding information of the
planned sample size of 8 unpublished studies with horizontal lines passing the y-axis at
√
ni.
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Figure 3: A funnel-plot for the clopidogrel study being modified by adding information of the
planned sample size of 3 unpublished studies with horizontal lines passing the y-axis at
√
ni.
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Table 1: Simulation results for estimation of θ with (α0, α1, ρ)=(-2.18,0.2,-0.4) and τ = 0.05, 0.15 or 0.30
(40% unpublished studies on average)
N +M = 15 N +M = 25 N +M = 50 N +M = 100
Scenario Method AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC
τ = 0.05 REML -0.285(0.094) 0.955 0.377 997 -0.282(0.067) 0.941 0.275 994 -0.280(0.046) 0.902 0.187 991 -0.277(0.032) 0.868 0.129 988
REML.KnHa -0.285(0.094) 0.944 0.413 997 -0.282(0.067) 0.931 0.286 994 -0.280(0.046) 0.892 0.186 991 -0.277(0.032) 0.861 0.128 988
Copas -0.273(0.099) 0.949 0.363 991 -0.267(0.075) 0.925 0.269 983 -0.264(0.058) 0.891 0.186 986 -0.255(0.048) 0.837 0.132 981
MLE(N) -0.257(0.112) 0.904 0.368 968 -0.251(0.077) 0.930 0.289 995 -0.249(0.054) 0.935 0.202 998 -0.248(0.035) 0.955 0.140 999
MLE(T) -0.257(0.112) 0.950 0.446 968 -0.251(0.077) 0.950 0.319 995 -0.249(0.054) 0.945 0.211 998 -0.248(0.035) 0.956 0.143 999
MLE(SE♯) -0.257(0.112) 0.952 0.483 968 -0.251(0.077) 0.957 0.330 995 -0.249(0.054) 0.947 0.213 998 -0.248(0.035) 0.957 0.144 999
τ = 0.15 REML -0.286(0.112) 0.920 0.420 999 -0.288(0.079) 0.913 0.310 993 -0.286(0.056) 0.893 0.216 994 -0.283(0.04) 0.854 0.153 997
REML.KnHa -0.286(0.112) 0.932 0.481 999 -0.288(0.079) 0.928 0.333 993 -0.286(0.056) 0.903 0.223 994 -0.283(0.04) 0.852 0.155 997
Copas -0.268(0.128) 0.873 0.392 984 -0.271(0.091) 0.879 0.299 986 -0.265(0.072) 0.862 0.215 993 -0.256(0.059) 0.825 0.156 996
MLE(N) -0.258(0.130) 0.849 0.403 963 -0.255(0.091) 0.899 0.325 990 -0.252(0.067) 0.921 0.237 995 -0.249(0.044) 0.943 0.171 1000
MLE(T) -0.258(0.130) 0.913 0.491 963 -0.255(0.091) 0.928 0.358 990 -0.252(0.067) 0.927 0.247 995 -0.249(0.044) 0.950 0.174 1000
MLE(SE♯) -0.258(0.13) 0.938 0.541 963 -0.255(0.091) 0.942 0.374 990 -0.252(0.067) 0.932 0.250 995 -0.249(0.044) 0.950 0.175 1000
τ = 0.30 REML -0.294(0.149) 0.905 0.544 999 -0.297(0.107) 0.899 0.414 999 -0.299(0.075) 0.888 0.296 1000 -0.295(0.054) 0.867 0.210 1000
REML.KnHa -0.294(0.149) 0.923 0.651 999 -0.297(0.107) 0.924 0.457 999 -0.299(0.075) 0.906 0.311 1000 -0.295(0.054) 0.881 0.216 1000
Copas -0.273(0.173) 0.852 0.508 967 -0.282(0.121) 0.866 0.412 982 -0.274(0.093) 0.861 0.294 993 -0.262(0.075) 0.843 0.223 996
MLE(N) -0.262(0.168) 0.827 0.529 947 -0.261(0.126) 0.876 0.442 984 -0.253(0.092) 0.915 0.334 994 -0.249(0.062) 0.948 0.244 999
MLE(T) -0.262(0.168) 0.884 0.643 947 -0.261(0.126) 0.900 0.488 984 -0.253(0.092) 0.921 0.349 994 -0.249(0.062) 0.958 0.249 999
MLE(SE♯) -0.262(0.168) 0.918 0.717 947 -0.261(0.126) 0.926 0.513 984 -0.253(0.092) 0.937 0.356 994 -0.249(0.062) 0.958 0.250 999
True -0.250 - - - -0.250 - - - -0.250 - - - -0.250 - - -
N,number of total studies;AVE, mean value of estimates;SD,standard error of estimates; CP, 95%confidence interval coverage probability;
LOCI,length of confidence interval;NOC,number of converged cases.
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Table 2: Simulation results for estimation of θ with (α0, α1, ρ)=(-2.18,0.2,-0.8) and τ = 0.05, 0.15 or 0.30
(40% unpublished studies on average)
N +M = 15 N +M = 25 N +M = 50 N +M = 100
Scenario Method AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC
τ = 0.05 REML -0.320(0.097) 0.913 0.376 998 -0.313(0.068) 0.881 0.272 992 -0.307(0.046) 0.789 0.186 992 -0.304(0.033) 0.644 0.128 983
REML.KnHa -0.320(0.097) 0.917 0.404 998 -0.313(0.068) 0.874 0.275 992 -0.307(0.046) 0.769 0.182 992 -0.304(0.033) 0.615 0.125 983
Copas -0.291(0.105) 0.906 0.365 982 -0.276(0.090) 0.862 0.267 969 -0.249(0.081) 0.773 0.190 933 -0.220(0.066) 0.664 0.138 929
MLE(N) -0.264(0.100) 0.918 0.352 971 -0.254(0.071) 0.942 0.264 995 -0.250(0.050) 0.946 0.186 1000 -0.249(0.033) 0.956 0.130 1000
MLE(T) -0.264(0.100) 0.968 0.426 971 -0.254(0.071) 0.957 0.291 995 -0.250(0.050) 0.954 0.194 1000 -0.249(0.033) 0.958 0.132 1000
MLE(SE♯) -0.264(0.100) 0.973 0.466 971 -0.254(0.071) 0.962 0.307 995 -0.250(0.050) 0.965 0.200 1000 -0.249(0.033) 0.959 0.134 1000
τ = 0.15 REML -0.323(0.107) 0.870 0.400 995 -0.322(0.080) 0.841 0.303 993 -0.319(0.056) 0.745 0.213 993 -0.316(0.041) 0.603 0.151 997
REML.KnHa -0.323(0.107) 0.886 0.450 995 -0.322(0.080) 0.860 0.321 993 -0.319(0.056) 0.759 0.218 993 -0.316(0.041) 0.611 0.152 997
Copas -0.286(0.130) 0.840 0.380 979 -0.278(0.110) 0.794 0.295 964 -0.249(0.096) 0.725 0.215 957 -0.215(0.078) 0.660 0.163 926
MLE(N) -0.266(0.116) 0.888 0.369 973 -0.259(0.084) 0.909 0.293 991 -0.254(0.061) 0.924 0.216 996 -0.249(0.041) 0.937 0.157 998
MLE(T) -0.266(0.116) 0.934 0.443 973 -0.259(0.084) 0.939 0.323 991 -0.254(0.061) 0.934 0.226 996 -0.249(0.041) 0.939 0.160 998
MLE(SE♯) -0.266(0.116) 0.954 0.493 973 -0.259(0.084) 0.950 0.348 991 -0.254(0.061) 0.942 0.235 996 -0.249(0.041) 0.944 0.162 998
τ = 0.30 REML -0.346(0.141) 0.832 0.517 999 -0.343(0.109) 0.832 0.406 998 -0.342(0.076) 0.748 0.292 1000 -0.339(0.054) 0.604 0.208 1000
REML.KnHa -0.346(0.141) 0.878 0.608 999 -0.343(0.109) 0.874 0.447 998 -0.342(0.076) 0.775 0.306 1000 -0.339(0.054) 0.613 0.213 1000
Copas -0.308(0.170) 0.791 0.483 955 -0.297(0.138) 0.809 0.395 960 -0.268(0.116) 0.765 0.299 965 -0.224(0.099) 0.729 0.236 951
MLE(N) -0.285(0.164) 0.822 0.484 942 -0.270(0.120) 0.875 0.406 982 -0.259(0.085) 0.917 0.314 985 -0.251(0.058) 0.943 0.225 986
MLE(T) -0.285(0.164) 0.877 0.581 942 -0.270(0.120) 0.900 0.447 982 -0.259(0.085) 0.929 0.328 985 -0.251(0.058) 0.946 0.229 986
MLE(SE♯) -0.285(0.164) 0.912 0.659 942 -0.270(0.120) 0.930 0.484 982 -0.259(0.085) 0.946 0.340 985 -0.251(0.058) 0.951 0.233 986
True -0.250 - - - -0.250 - - - -0.250 - - - -0.250 - - -
N,number of total studies;AVE, mean value of estimates;SD,standard error of estimates; CP, 95%confidence interval coverage probability;
LOCI,length of confidence interval;NOC,number of converged cases.
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Table 3: Summary of the statistical analysis for publication bias evaluation of tiotropium study:
# implies expected number of unpublished studies in the sensitivity analysis with the Copas selection model
Description Method # OR 95% CI P-value
No adjustment REML - 0.768 [0.697, 0.847] <.000
REML-KnHa - 0.768 [0.691, 0.854] <.000
Sensitivity analysis Copas 1 0.779 [0.707, 0.858] <.000
5 0.795 [0.712, 0.886] <.000
8 0.803 [0.717, 0.898] <.000
11 0.808 [0.720, 0.907] <.000
13 0.811 [0.721, 0.912] 0.001
Proposed MLE(N) - 0.787 [0.710, 0.873] <.000
MLE(T) - 0.787 [0.706, 0.878] <.000
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Table 4: Summary of the statistical analysis for publication bias evaluation of clopidogrel study:
# implies expected number of unpublished studies in the sensitivity analysis with the Copas selection model
Description Method # OR 95% CI P-value
No adjustment REML - 0.579 [0.375, 0.892] 0.013
REML-KnHa - 0.579 [0.385, 0.871] 0.013
Sensitivity analysis Copas 2 0.690 [0.501, 0.952] 0.024
3 0.708 [0.514, 0.975] 0.034
4 0.740 [0.537, 1.020] 0.066
6 0.805 [0.503, 1.288] 0.365
8 0.782 [0.437, 1.397] 0.406
Proposed MLE(N) - 0.692 [0.496, 0.967] 0.031
MLE(T) - 0.692 [0.476, 1.007] 0.054
MLE(SE♯) - 0.692 [0.460, 1.041] 0.073
2
0
Web-appendix to “Using clinical trial registries to inform Copas
selection model for publication bias in meta-analysis”
Abstract
In Web-appendix A, we provide the datasets of the tiotropium study and the clopidogrel
study with information of published/unpublished studies. In Web-appendix B we present
the results of simulation studies with (α0, α1)=(-1.24,0.16) and (-0.58,0.13), respectively.
Web-appendix A: Tables for the datasets of the tiotropium
study and the clopidogrel study
In this appendix, we presented the datasets of the tiotropium study and the clopidogrel study.
In Table S1, the dataset of the tiotropium study was presented. Studies from No.1 to No.22
came from the original meta-analysis by Karner et al.[1] which we introduced in Subsection 2.1.
By searching with multiple clinical trial registries, we further identified 10 studies with the same
search terms: Tiotropium or Spiriva or HandiHaler or Respimat as the original meta-analysis.
The identified 10 studies referred to the studies as from No.23 to No.32. Recall that Di is an
indicator of publication status; Di = 1 if published and Di = 0 otherwise. Among these ten
studies, study No.23 and No.24 reported estimated treatment effects in clinical trial registries.
Therefore, they had the same indicator Di = 1 as the original study No.1 to No.22. The rest
of them (from No.25 to No.32) were deemed as unpublished studies with the indicator Di = 0.
The column of “Status” denotes the status of publication and registration. Studies marked
with “published & regsitered” means we can identify these studies from both online literature
database and clinical trial registries, while those marked with “published” or “’registered’ means
they can only be identified from the online literature database or clinical trial registries.
In Table S2, the dataset of the clopidogrel study was presented. Similarly to the dataset
of the tiotropium study, studies with Di = 1 (from No.1 to No.12) came from the original
meta-analysis by Chen et al. [2]. The studies with Di = 0 were identified from the clinical trial
registries.
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Table S1: Tiotropium dataset
Tiotropium Placebo
No. Study Events Total Events Total ni logORi si Di Status
1 Bateman 2010a 685 1989 842 2002 3991 -0.33 0.07 1 published & registered
2 Bateman 2010b 495 1337 288 653 1990 -0.29 0.10 1 published & registered
3 Beeh 2006 180 1236 80 403 1639 -0.37 0.15 1 published & registered
4 Brusasco 2003 129 402 156 400 802 -0.30 0.15 1 published
5 Casaburi 2002 198 550 156 371 921 -0.25 0.14 1 published
6 Chan 2007 268 608 125 305 913 0.13 0.14 1 published & registered
7 Cooper 2010 112 260 102 259 519 0.15 0.18 1 published & registered
8 Covelli 2005 9 100 12 96 196 -0.37 0.47 1 published & registered
9 Dusser 2006 213 500 272 510 1010 -0.43 0.13 1 published & registered
10 Freeman 2007 19 200 35 195 395 -0.73 0.30 1 published & registered
11 Johansson 2008 2 107 4 117 224 -0.62 0.88 1 published & registered
12 Magnussen 2008 13 228 26 244 472 -0.67 0.35 1 published & registered
13 Moita 2008 6.00 147 6 164 311 0.11 0.59 1 published & registered
14 NCT00144326 11 123 12 127 250 -0.06 0.44 1 registered
15 Niewoehner 2005 255 914 296 915 1829 -0.21 0.10 1 published & registered
16 Powrie 2007 30 69 47 73 142 -0.84 0.34 1 published & registered
17 Sun 2007 0 30 2 30 60 -1.66 1.57 1 published
18 Tashkin 2008 2001 2987 2049 3006 5993 -0.05 0.06 1 published & registered
19 Tonnel 2008 101 266 130 288 554 -0.30 0.17 1 published & registered
20 Trooster 2011 11 238 24 219 457 -0.94 0.38 1 published & registered
21 Verkinde 2006 10 46 8 54 100 0.47 0.52 1 published
22 Voshaar 2008 43 360 21 181 541 0.03 0.28 1 published & registered
23 NCT01202188 85 480 60 232 712 -0.48 0.19 1 registered
24 NCT00929110 80 266 107 266 532 -0.45 0.18 1 registered
25 NCT00668772 207 0 registered
26 NCT00662740 220 0 registered
27 NCT00157235 234 0 registered
28 NCT00274521 108 0 registered
29 NCT02172287 623 0 registered
30 NCT02173691 584 0 registered
31 2007-001946-42-ES 844 0 registered
32 2005-000650-79 389 0 registered
2
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Table S2: Clopidogrel dataset
High Dose Standard Dose
No. Study Events Total Events Total ni logORi si Di Status
1 Aradi 2012 1 36 8 38 74 -2.23 1.09 1 published & registered
2 DOUBLE 2010 0 24 1 24 48 -1.14 1.66 1 published
3 EFFICIENT 2011 2 47 8 47 94 -1.53 0.82 1 published & registered
4 GRAVITAS 2011 25 1109 25 1105 2214 -0.00 0.29 1 published & registered
5 Gremmel 2011 1 21 2 23 44 -0.64 1.26 1 published
6 Han 2009 4 403 9 410 813 -0.81 0.61 1 published
7 Ren LH 2012 6 46 10 55 101 -0.39 0.56 1 published
8 Roghani 2011 4 205 2 195 400 0.65 0.87 1 published
9 Tousek 2011 1 30 2 30 60 -0.73 1.25 1 published
10 VASP-02 2008 0 58 1 62 120 -1.05 1.64 1 published & registered
11 von Beckerath 2007 1 31 1 29 60 -0.07 1.44 1 published
12 Wang 2011 14 150 30 156 306 -0.84 0.35 1 published
13 NCT01069302 106 0 registered
14 NCT01371058 350 0 registered
15 NCT01102439 82 0 registered
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Web-appendix B: Tables for simulation results with addi-
tional settings
In this appendix, we presented the results of simulation studies with (α0, α1)=(-1.24,0.16) (Table
S3 and Table S4) and (-0.58,0.13) (Table S5 and Table S6), which resulted in the 27% and 19%
unpublished studies on average, respectively. The findings of these two settings were similar
with the results in Tables 1 and 2. We observed that our method had the smallest biases in
all the scenarios in comparison to the REML and the Copas sensitivity analysis method. With
larger number of studies (N=50 and 100), the confidence intervals of our method based on the
normal approximation had emperical coverage probabilities close to the nominal level of 95%.
With smaller number of studies (N=15 and 25), the modified confidence intervals could be
useful to improve the coverage probabilities of our method when between-study variance was
considerable.
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Table S3: Simulation results for estimation of θ with (α0, α1, ρ)=(-1.24,0.16,-0.4) and τ = 0.05, 0.15 or 0.30
(27% unpublished studies on average)
N +M = 15 N +M = 25 N +M = 50 N +M = 100
Scenario Method AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC
τ = 0.05 REML -0.280(0.083) 0.957 0.353 991 -0.276(0.063) 0.942 0.262 997 -0.275(0.044) 0.915 0.179 988 -0.272(0.031) 0.891 0.124 989
REML.KnHa -0.280(0.083) 0.954 0.370 991 -0.276(0.063) 0.945 0.265 997 -0.275(0.044) 0.901 0.177 988 -0.272(0.031) 0.882 0.122 989
Copas -0.270(0.092) 0.944 0.344 994 -0.268(0.066) 0.943 0.257 992 -0.263(0.054) 0.896 0.178 991 -0.257(0.040) 0.870 0.126 989
MLE(N) -0.261(0.096) 0.927 0.351 972 -0.253(0.072) 0.932 0.272 994 -0.250(0.053) 0.930 0.191 999 -0.249(0.034) 0.952 0.135 999
MLE(T) -0.261(0.096) 0.954 0.402 972 -0.253(0.072) 0.948 0.293 994 -0.250(0.053) 0.935 0.198 999 -0.249(0.034) 0.954 0.138 999
MLE(SE♯) -0.261(0.096) 0.965 0.422 972 -0.253(0.072) 0.953 0.300 994 -0.250(0.053) 0.937 0.200 999 -0.249(0.034) 0.954 0.138 999
τ = 0.15 REML -0.287(0.099) 0.920 0.390 994 -0.280(0.074) 0.919 0.293 990 -0.281(0.053) 0.900 0.205 993 -0.278(0.038) 0.878 0.145 997
REML.KnHa -0.287(0.099) 0.925 0.426 994 -0.280(0.074) 0.923 0.307 990 -0.281(0.053) 0.908 0.209 993 -0.278(0.038) 0.880 0.146 997
Copas -0.276(0.109) 0.898 0.371 992 -0.267(0.085) 0.894 0.285 993 -0.263(0.070) 0.861 0.203 996 -0.259(0.049) 0.863 0.148 998
MLE(N) -0.264(0.120) 0.871 0.379 973 -0.255(0.085) 0.913 0.304 995 -0.252(0.064) 0.912 0.225 1000 -0.250(0.042) 0.941 0.163 1000
MLE(T) -0.264(0.120) 0.916 0.435 973 -0.255(0.085) 0.931 0.328 995 -0.252(0.064) 0.921 0.233 1000 -0.250(0.042) 0.944 0.165 1000
MLE(SE♯) -0.264(0.120) 0.934 0.466 973 -0.255(0.085) 0.946 0.340 995 -0.252(0.064) 0.924 0.235 1000 -0.250(0.042) 0.945 0.166 1000
τ = 0.30 REML -0.286(0.134) 0.917 0.505 998 -0.293(0.103) 0.906 0.389 999 -0.291(0.072) 0.895 0.277 1000 -0.288(0.051) 0.882 0.197 1000
REML.KnHa -0.286(0.134) 0.940 0.570 998 -0.293(0.103) 0.917 0.417 999 -0.291(0.072) 0.912 0.287 1000 -0.288(0.051) 0.887 0.200 1000
Copas -0.271(0.150) 0.872 0.479 985 -0.275(0.119) 0.868 0.378 996 -0.271(0.089) 0.864 0.274 997 -0.265(0.065) 0.866 0.201 998
MLE(N) -0.261(0.153) 0.859 0.503 962 -0.264(0.119) 0.885 0.413 985 -0.254(0.087) 0.930 0.313 995 -0.250(0.059) 0.942 0.228 999
MLE(T) -0.261(0.153) 0.905 0.577 962 -0.264(0.119) 0.905 0.445 985 -0.254(0.087) 0.943 0.324 995 -0.250(0.059) 0.943 0.232 999
MLE(SE♯) -0.261(0.153) 0.928 0.619 962 -0.264(0.119) 0.922 0.460 985 -0.254(0.087) 0.948 0.327 995 -0.250(0.059) 0.946 0.232 999
True -0.250 - - - -0.250 - - - -0.250 - - - -0.250 - - -
N,number of total studies;AVE, mean value of estimates;SD,standard error of estimates; CP, 95%confidence interval coverage probability;
LOCI,length of confidence interval;NOC,number of converged cases.
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Table S4: Simulation results for estimation of θ with (α0, α1, ρ)=(-1.24,0.16,-0.8) and τ = 0.05, 0.15 or 0.30
(27% unpublished studies on average)
N +M = 15 N +M = 25 N +M = 50 N +M = 100
Scenario Method AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC
τ = 0.05 REML -0.304(0.084) 0.932 0.345 989 -0.302(0.063) 0.901 0.258 991 -0.297(0.043) 0.840 0.177 985 -0.295(0.031) 0.712 0.123 982
REML.KnHa -0.304(0.084) 0.912 0.348 989 -0.302(0.063) 0.881 0.251 991 -0.297(0.043) 0.811 0.168 985 -0.295(0.031) 0.669 0.116 982
Copas -0.281(0.097) 0.912 0.336 985 -0.274(0.081) 0.888 0.254 983 -0.259(0.069) 0.824 0.179 958 -0.234(0.058) 0.728 0.130 969
MLE(N) -0.262(0.088) 0.933 0.331 981 -0.255(0.068) 0.931 0.252 994 -0.251(0.047) 0.939 0.177 998 -0.249(0.031) 0.952 0.123 1000
MLE(T) -0.262(0.088) 0.958 0.379 981 -0.255(0.068) 0.952 0.271 994 -0.251(0.047) 0.945 0.184 998 -0.249(0.031) 0.956 0.125 1000
MLE(SE♯) -0.262(0.088) 0.963 0.398 981 -0.255(0.068) 0.955 0.280 994 -0.251(0.047) 0.950 0.186 998 -0.249(0.031) 0.956 0.126 1000
τ = 0.15 REML -0.317(0.100) 0.902 0.380 994 -0.310(0.074) 0.870 0.286 989 -0.307(0.052) 0.800 0.201 992 -0.305(0.038) 0.664 0.142 994
REML.KnHa -0.317(0.100) 0.899 0.404 994 -0.310(0.074) 0.869 0.292 989 -0.307(0.052) 0.793 0.200 992 -0.305(0.038) 0.658 0.140 994
Copas -0.290(0.118) 0.874 0.366 989 -0.274(0.100) 0.832 0.280 988 -0.256(0.088) 0.760 0.201 978 -0.231(0.070) 0.690 0.151 964
MLE(N) -0.274(0.116) 0.884 0.361 968 -0.259(0.080) 0.906 0.282 995 -0.254(0.057) 0.918 0.207 993 -0.250(0.038) 0.938 0.148 999
MLE(T) -0.274(0.116) 0.928 0.414 968 -0.259(0.080) 0.925 0.303 995 -0.254(0.057) 0.928 0.214 993 -0.250(0.038) 0.941 0.151 999
MLE(SE♯) -0.274(0.116) 0.939 0.444 968 -0.259(0.080) 0.937 0.318 995 -0.254(0.057) 0.938 0.218 993 -0.250(0.038) 0.943 0.152 999
τ = 0.30 REML -0.322(0.135) 0.878 0.482 1000 -0.328(0.099) 0.862 0.377 999 -0.327(0.070) 0.797 0.272 1000 -0.324(0.051) 0.668 0.193 1000
REML.KnHa -0.322(0.135) 0.899 0.537 1000 -0.328(0.099) 0.877 0.401 999 -0.327(0.070) 0.808 0.279 1000 -0.324(0.051) 0.675 0.194 1000
Copas -0.290(0.156) 0.824 0.459 968 -0.288(0.130) 0.804 0.369 985 -0.270(0.106) 0.779 0.275 991 -0.239(0.091) 0.726 0.213 990
MLE(N) -0.272(0.149) 0.851 0.464 975 -0.270(0.109) 0.882 0.384 986 -0.259(0.079) 0.931 0.294 994 -0.251(0.054) 0.946 0.211 991
MLE(T) -0.272(0.149) 0.893 0.531 975 -0.270(0.109) 0.906 0.413 986 -0.259(0.079) 0.939 0.304 994 -0.251(0.054) 0.950 0.215 991
MLE(SE♯) -0.272(0.149) 0.917 0.578 975 -0.270(0.109) 0.924 0.433 986 -0.259(0.079) 0.947 0.311 994 -0.251(0.054) 0.952 0.217 991
True -0.250 - - - -0.250 - - - -0.250 - - - -0.250 - - -
N,number of total studies;AVE, mean value of estimates;SD,standard error of estimates; CP, 95%confidence interval coverage probability;
LOCI,length of confidence interval;NOC,number of converged cases.
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Table S5: Simulation results for estimation of θ with (α0, α1, ρ)=(-0.58,0.13,-0.4) and τ = 0.05, 0.15 or 0.30
(19% unpublished studies on average)
N +M = 15 N +M = 25 N +M = 50 N +M = 100
Scenario Method AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC
τ = 0.05 REML -0.274(0.082) 0.960 0.346 994 -0.268(0.063) 0.941 0.254 989 -0.271(0.043) 0.932 0.176 987 -0.268(0.031) 0.911 0.122 985
REML.KnHa -0.274(0.082) 0.945 0.357 994 -0.268(0.063) 0.934 0.254 989 -0.271(0.043) 0.922 0.172 987 -0.268(0.031) 0.903 0.119 985
Copas -0.265(0.088) 0.951 0.337 996 -0.261(0.067) 0.928 0.250 997 -0.261(0.051) 0.908 0.174 992 -0.258(0.036) 0.898 0.122 995
MLE(N) -0.261(0.095) 0.928 0.343 969 -0.253(0.071) 0.929 0.260 996 -0.253(0.050) 0.934 0.186 998 -0.250(0.033) 0.944 0.132 1000
MLE(T) -0.261(0.095) 0.954 0.386 969 -0.253(0.071) 0.940 0.277 996 -0.253(0.050) 0.943 0.192 998 -0.250(0.033) 0.951 0.134 1000
MLE(SE♯) -0.261(0.095) 0.961 0.403 969 -0.253(0.071) 0.942 0.283 996 -0.253(0.050) 0.944 0.194 998 -0.250(0.033) 0.951 0.134 1000
τ = 0.15 REML -0.274(0.096) 0.940 0.378 995 -0.269(0.074) 0.929 0.286 986 -0.275(0.052) 0.912 0.200 991 -0.272(0.037) 0.904 0.142 997
REML.KnHa -0.274(0.096) 0.932 0.406 995 -0.269(0.074) 0.933 0.295 986 -0.275(0.052) 0.917 0.203 991 -0.272(0.037) 0.904 0.142 997
Copas -0.264(0.103) 0.916 0.363 995 -0.258(0.082) 0.905 0.278 993 -0.263(0.064) 0.883 0.203 999 -0.260(0.044) 0.892 0.143 996
MLE(N) -0.256(0.108) 0.905 0.371 959 -0.251(0.082) 0.898 0.294 994 -0.255(0.061) 0.917 0.216 999 -0.251(0.041) 0.937 0.159 1000
MLE(T) -0.256(0.108) 0.935 0.418 959 -0.251(0.082) 0.922 0.314 994 -0.255(0.061) 0.925 0.223 999 -0.251(0.041) 0.938 0.162 1000
MLE(SE♯) -0.256(0.108) 0.949 0.442 959 -0.251(0.082) 0.931 0.323 994 -0.255(0.061) 0.927 0.225 999 -0.251(0.041) 0.938 0.162 1000
τ = 0.30 REML -0.280(0.125) 0.917 0.480 997 -0.284(0.100) 0.914 0.375 999 -0.283(0.069) 0.909 0.268 1000 -0.280(0.050) 0.896 0.191 1000
REML.KnHa -0.280(0.125) 0.927 0.531 997 -0.284(0.100) 0.924 0.398 999 -0.283(0.069) 0.919 0.277 1000 -0.280(0.050) 0.898 0.193 1000
Copas -0.264(0.143) 0.880 0.460 989 -0.272(0.109) 0.881 0.366 998 -0.269(0.082) 0.880 0.266 998 -0.264(0.059) 0.879 0.193 1000
MLE(N) -0.261(0.142) 0.878 0.472 961 -0.265(0.113) 0.889 0.390 982 -0.257(0.083) 0.926 0.297 996 -0.252(0.058) 0.931 0.220 1000
MLE(T) -0.261(0.142) 0.904 0.531 961 -0.265(0.113) 0.908 0.416 982 -0.257(0.083) 0.932 0.306 996 -0.252(0.058) 0.936 0.223 1000
MLE(SE♯) -0.261(0.142) 0.922 0.564 961 -0.265(0.113) 0.916 0.428 982 -0.257(0.083) 0.937 0.309 996 -0.252(0.058) 0.937 0.223 1000
True -0.250 - - - -0.250 - - - -0.250 - - - -0.250 - - -
N,number of total studies;AVE, mean value of estimates;SD,standard error of estimates; CP, 95%confidence interval coverage probability;
LOCI,length of confidence interval;NOC,number of converged cases.
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Table S6: Simulation results for estimation of θ with (α0, α1, ρ)=(-0.58,0.13,-0.8) and τ = 0.05, 0.15 or 0.30
(19% unpublished studies on average)
N +M = 15 N +M = 25 N +M = 50 N +M = 100
Scenario Method AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC AVE(SD) CP LOCI NOC
τ = 0.05 REML -0.297(0.083) 0.939 0.340 989 -0.289(0.058) 0.929 0.253 990 -0.288(0.042) 0.870 0.173 985 -0.286(0.030) 0.791 0.120 980
REML.KnHa -0.297(0.083) 0.917 0.332 989 -0.289(0.058) 0.917 0.240 990 -0.288(0.042) 0.841 0.162 985 -0.286(0.030) 0.750 0.112 980
Copas -0.281(0.090) 0.932 0.333 995 -0.271(0.072) 0.913 0.250 989 -0.264(0.061) 0.854 0.174 974 -0.248(0.052) 0.774 0.123 962
MLE(N) -0.267(0.090) 0.932 0.327 976 -0.255(0.066) 0.941 0.249 995 -0.253(0.047) 0.936 0.173 999 -0.250(0.031) 0.956 0.120 1000
MLE(T) -0.267(0.090) 0.958 0.368 976 -0.255(0.066) 0.958 0.266 995 -0.253(0.047) 0.941 0.178 999 -0.250(0.031) 0.958 0.122 1000
MLE(SE♯) -0.267(0.090) 0.966 0.382 976 -0.255(0.066) 0.962 0.272 995 -0.253(0.047) 0.944 0.180 999 -0.250(0.031) 0.958 0.123 1000
τ = 0.15 REML -0.295(0.097) 0.913 0.368 988 -0.293(0.072) 0.902 0.279 987 -0.296(0.051) 0.839 0.195 989 -0.294(0.037) 0.756 0.138 992
REML.KnHa -0.295(0.097) 0.915 0.381 988 -0.293(0.072) 0.899 0.278 987 -0.296(0.051) 0.834 0.192 989 -0.294(0.037) 0.733 0.134 992
Copas -0.276(0.109) 0.877 0.359 988 -0.267(0.094) 0.849 0.272 986 -0.263(0.078) 0.802 0.195 990 -0.248(0.061) 0.754 0.143 973
MLE(N) -0.265(0.105) 0.883 0.352 963 -0.256(0.081) 0.904 0.277 993 -0.257(0.057) 0.916 0.200 1000 -0.251(0.038) 0.932 0.144 1000
MLE(T) -0.265(0.105) 0.915 0.396 963 -0.256(0.081) 0.930 0.296 993 -0.257(0.057) 0.924 0.206 1000 -0.251(0.038) 0.936 0.146 1000
MLE(SE♯) -0.265(0.105) 0.929 0.417 963 -0.256(0.081) 0.936 0.305 993 -0.257(0.057) 0.932 0.209 1000 -0.251(0.038) 0.940 0.146 1000
τ = 0.30 REML -0.310(0.129) 0.887 0.470 994 -0.312(0.096) 0.885 0.362 998 -0.312(0.068) 0.838 0.262 1000 -0.309(0.049) 0.761 0.186 1000
REML.KnHa -0.310(0.129) 0.901 0.513 994 -0.312(0.096) 0.891 0.379 998 -0.312(0.068) 0.840 0.266 1000 -0.309(0.049) 0.756 0.186 1000
Copas -0.284(0.149) 0.847 0.450 982 -0.286(0.119) 0.851 0.356 994 -0.273(0.097) 0.803 0.261 996 -0.256(0.077) 0.779 0.195 994
MLE(N) -0.278(0.145) 0.848 0.459 961 -0.272(0.108) 0.887 0.375 986 -0.261(0.077) 0.920 0.277 990 -0.252(0.052) 0.942 0.201 994
MLE(T) -0.278(0.145) 0.889 0.517 961 -0.272(0.108) 0.901 0.401 986 -0.261(0.077) 0.932 0.285 990 -0.252(0.052) 0.950 0.204 994
MLE(SE♯) -0.278(0.145) 0.911 0.550 961 -0.272(0.108) 0.916 0.414 986 -0.261(0.077) 0.936 0.289 990 -0.252(0.052) 0.950 0.205 994
True -0.250 - - - -0.250 - - - -0.250 - - - -0.250 - - -
N,number of total studies;AVE, mean value of estimates;SD,standard error of estimates; CP, 95%confidence interval coverage probability;
LOCI,length of confidence interval;NOC,number of converged cases.
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